YAP1-NUTM1 Gene Fusion in Eccrine Porocarcinoma with Late Metastatic Recurrence: A Case Report
DOI:
https://doi.org/10.2340/actadv.v102.2417Keywords:
eccrine, porocarcinoma, metastaticAbstract
Abstract is missing (Short communication)
Downloads
References
Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine porocarcinoma: new insights and a systematic review of the literature. Dermatol Surg 2018; 44: 1247-1261.
https://doi.org/10.1097/DSS.0000000000001566
Salih AM, Kakamad FH, Baba HO, Salih RQ, Hawbash MR, Mohammed SH, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann Med Surg (Lond) 2017; 20: 74-79.
https://doi.org/10.1016/j.amsu.2017.06.027
Sekine S, Kiyono T, Ryo E, Ogawa R, Wakai S, Ichikawa H, et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest 2019; 129: 3827-3832.
https://doi.org/10.1172/JCI126185
Gómez-Zubiaur A, Medina-Montalvo S, Vélez-Velázquez MD, Polo-Rodríguez I. Eccrine porocarcinoma: patient characteristics, clinical and histopathologic features, and treatment in 7 cases. Actas Dermosifiliogr 2017; 108: e27-e32.
https://doi.org/10.1016/j.adengl.2017.03.002
Macagno N, Kervarrec T, Sohier P, Poirot B, Haffner A, Carlotti A, et al. NUT Is a specific immunohistochemical marker for the diagnosis of yap1-nutm1-rearranged cutaneous poroid neoplasms. Am J Surg Pathol 2021; 45: 1221-1227.
https://doi.org/10.1097/PAS.0000000000001693
Prieto-Granada C, Morlote D, Pavlidakey P, Rodriguez-Waitkus P, Ramirez C, Florento E, et al. Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: a series of six YAP1-rearranged adnexal skin tumors. J Cutan Pathol 2021; 48: 1139-1149.
https://doi.org/10.1111/cup.14008
Parra O, Kerr DA, Bridge JA, Loehrer AP, Linos K. A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility. J Cutan Pathol 2021; 48: 95-101.
https://doi.org/10.1111/cup.13832
Russell-Goldman E, Hornick JL, Hanna J. Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma. J Cutan Pathol 2021; 48: 403-410.
https://doi.org/10.1111/cup.13924
Godillot C, Boulinguez S, Riffaud L, Sibaud V, Chira C, Tournier E, et al. Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. Eur J Cancer 2018; 90: 142-145.
https://doi.org/10.1016/j.ejca.2017.11.009
Belin E, Ezzedine K, Stanislas S, Lalanne N, Beylot-Barry M, Taieb A, et al. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. Br J Dermatol 2011; 165: 985-989.
https://doi.org/10.1111/j.1365-2133.2011.10486.x
Lee KA, Cioni M, Robson A, Bataille V. Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab. BMJ Case Rep 2019; 12: e228917.
Published
How to Cite
License
Copyright (c) 2022 Sara Tormo-Mainar, Joana Vidal, Marta Salido, Ramon M. Pujol, Gustavo Deza
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
